Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Quarterly results
ADMA BIOLOGICS, INC. (ADMA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 4 Grossman Adam S (President and CEO) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Paid exercise price by delivering 18,718 shares @ $3.58, valued at $67k
10/03/2023 4 LENZ BRIAN (EVP, CFO) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Paid exercise price by delivering 15,268 shares @ $3.58, valued at $54.7k
10/02/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
10/02/2023 8-K Quarterly results
08/24/2023 4 KWON YOUNG (Director) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Bought 25,000 shares @ $3.9, valued at $97.5k
08/23/2023 4 Fong Bryant (Director) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Sold 1,433,304 shares @ $3.8685, valued at $5.5M
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/18/2023 4 Grossman Adam S (President and CEO) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Sold 250,000 shares @ $4.1534, valued at $1M
08/18/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
08/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/17/2023 4 LENZ BRIAN (EVP, CFO) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Sold 211,578 shares @ $4.5975, valued at $972.7k
Paid exercise price by delivering 631,078 shares @ $4.61, valued at $2.9M
Sold 178,184 shares @ $4.4527, valued at $793.4k
Exercised 97,395 options to buy @ $1.67, valued at $162.6k
Exercised 83,979 options to buy @ $2.35, valued at $197.4k
Exercised 85,416 options to buy @ $2.92, valued at $249.4k
Exercised 200,000 options to buy @ $3.22, valued at $644k
Exercised 150,000 options to buy @ $3.71, valued at $556.5k
Exercised 192,472 options to buy @ $3.66, valued at $704.4k
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "RAMSEY, N.J. and BOCA RATON, Fla., Aug 9, 2023"
07/19/2023 8-K Quarterly results
07/05/2023 4 LENZ BRIAN (EVP, CFO) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Paid exercise price by delivering 15,268 shares @ $3.69, valued at $56.3k
07/05/2023 4 Grossman Adam S (President and CEO) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Paid exercise price by delivering 20,051 shares @ $3.69, valued at $74k
06/06/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "RAMSEY, N.J. and BOCA RATON, Fla., May 10, 2023 -- ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its first quarter 2023 financial results and provided a business update."
05/02/2023 8-K Credit agreement amendment
Docs: "Form of Warrant to Purchase Common Stock",
"Amendment No. 2 to the Credit and Guaranty Agreement",
"ADMA and our willingness to amend the previously underwritten terms speak to the above-expectation commercial execution.”"
04/13/2023 ARS Form ARS - Annual Report to Security Holders:
04/13/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/13/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/04/2023 4 LENZ BRIAN (EVP, CFO) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Paid exercise price by delivering 15,469 shares @ $3.31, valued at $51.2k
04/04/2023 4 Grossman Adam S (President and CEO) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Paid exercise price by delivering 17,853 shares @ $3.31, valued at $59.1k
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Quarterly results
Docs: "RAMSEY, N.J. and BOCA RATON, Fla., March 23, 2023 -- ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its fourth quarter and full year 2022 financial results and provided a business update."
03/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/08/2023 4 Grossman Adam S (President and CEO) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Paid exercise price by delivering 4,018 shares @ $3.42, valued at $13.7k
Paid exercise price by delivering 14,412 shares @ $3.42, valued at $49.3k
Paid exercise price by delivering 7,507 shares @ $3.55, valued at $26.6k
Granted 573,695 shares @ $0
Paid exercise price by delivering 23,607 shares @ $3.4, valued at $80.3k
Granted 1,147,385 options to buy @ $3.35, valued at $3.8M
03/08/2023 4 LENZ BRIAN (EVP, CFO) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Paid exercise price by delivering 1,559 shares @ $3.42, valued at $5.3k
Paid exercise price by delivering 7,927 shares @ $3.42, valued at $27.1k
Paid exercise price by delivering 5,000 shares @ $3.55, valued at $17.8k
Granted 135,175 shares @ $0
Paid exercise price by delivering 16,965 shares @ $3.4, valued at $57.7k
Granted 270,345 options to buy @ $3.35, valued at $905.7k
03/08/2023 4 Grossman Jerrold B (Director) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Granted 25,815 shares @ $0
Granted 51,630 options to buy @ $3.35, valued at $173k
03/08/2023 4 ELMS STEVE (Director) has filed a Form 4 on ADMA BIOLOGICS, INC.
Txns: Granted 25,815 shares @ $0
Granted 51,630 options to buy @ $3.35, valued at $173k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy